Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial-Reference-Cited by-同舟云学术

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial

Published:2019-12 Issue: Volume:70 Page:157-163
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

Olafson Lauren R.,Siddell Anna H.,Field Kathryn M.,Byrnes Madeleine,Rapkins Robert W.,Ng Benedict,Nixdorf Sheri,Barnes Elizabeth H.,Johns Terrance G.,Yip Sonia,Simes John,Nowak Anna K.,Rosenthal Mark A.,McDonald Kerrie L.

Funder

Roche Products Australia Pty Ltd

National Health and Medical Research Council of Australia

Cure Brain Cancer Foundation

Publisher

Elsevier BV

Subject

Physiology (medical),Neurology (clinical),Neurology,General Medicine,Surgery

Reference43 articles.

1. Bevacizumab and glioblastoma: past, present, and future directions;Kim;Cancer J,2018

2. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma;Kreisl;J Clin Oncol,2009

3. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial;Taal;Lancet Oncol,2014

4. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma;Vredenburgh;Clin Cancer Res,2007

5. Lomustine and bevacizumab in progressive glioblastoma;Wick;N Engl J Med,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma;Frontiers in Neurology;2023-05-25

2. Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors;Anticancer Research;2022-12

3. Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours;PLOS ONE;2021-10-01